Biocon Biologics receives UK MHRA marketing authorisations for Vevzuo and Evfraxy
Vevzuo is authorized for the prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone. Vevzuo is also authorized for the treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity.
Evfraxy is authorized for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women this significantly reduces the risk of vertebral, non-vertebral, and hip fractures. Furthermore, Evfraxy is authorized for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. In men with prostate cancer receiving hormone ablation, this significantly reduces the risk of vertebral fractures. Evfraxy is also authorized for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture.
Clinical data showed that both Denosumab biosimilars have comparable safety and efficacy to the reference product.
In Europe, the European Commission (EC) recently granted marketing authorisation for Biocon Biologics Denosumab biosimilars, allowing their commercialization in all European Union (EU) member states and the European Economic Area (EEA).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
16 hours ago
- Time of India
UKHSA warns: How antidepressants and other drugs can raise your risk in hot weather
Summer sunshine feels great until your prescription starts working against you. The UK Health Security Agency (UKHSA) has sounded the alarm: common medications can impair your ability to cope with hot weather, increasing risks of dehydration, heat exhaustion, and even heatstroke. And this isn't just an elder-living-in-a-care-home problem—it's for anyone in sunny conditions taking these meds. Normally, your body cools itself by sweating, adjusting blood flow near your skin, and maintaining fluid balance. But certain medications mess with these systems and can throw your internal thermostat off balance. Take diuretics and blood pressure drugs like ACE inhibitors, beta-blockers, or calcium channel blockers. These meds can dehydrate you by increasing urination, suppressing thirst, and limiting blood flow shifts. That means less sweating, less cooling—and less ability to roll with soaring temps. The MHRA (Medicines and Healthcare products Regulatory Agency) specifically calls out these drugs as raising your heat risk during warm spells. Then you've got mental health drugs—SSRI and TCA antidepressants, antipsychotics, and ADHD stimulants like methylphenidate. They can stop your body from sweating enough, boost your core temperature, and make it harder for your brain to detect overheating. Even antibiotics like doxycycline ramp up sun sensitivity, making a short walk outside unexpectedly scorching. Meanwhile, NSAIDs and some supplements put extra stress on your kidneys during dehydration—meaning your meds can make the heat hit harder than usual. When pills go off script in the heat It's not just about side effects. Heat itself can degrade medication. Insulin, and certain antibiotics can become less effective if stored above recommended temps—usually around 25°C. Picture leaving your insulin vials baking in a hot car or your pills in a backpack at the beach. The MHRA warns these medications can lose potency, or even become dangerously unstable. Heatproofing your health routine So what should you do if you're on these meds and the thermometer spikes? Start with storing meds properly. Keep them out of direct sunlight, avoid cars in midday heat, and check that bottles haven't changed color or texture. Know where your fridge's cooler spots are, and move meds into them when needed. Then there's personal heat readiness. Stay hydrated and don't wait until you're thirsty—those on diuretics or antihypertensives might not feel typical thirst signals. Look out for dizziness, headaches, confusion, or dark urine: classic heat-exhaustion signs. If you're on any meds that affect your body's heat response—SSRIs, beta-blockers, ADHD meds—think ahead. Limit outdoor time during peak sun hours from 11am to 3pm. Stick to light clothing, stay in shade, and chill out indoors when the heat's too much. Who's most at risk? This isn't just doom-saying. Heat-health alerts like the UK's yellow and amber warnings are being issued more frequently, and the public health impact is real. England recorded over 1,300 heat-related deaths last summer, and medicines were a big contributor. Elderly people, kids, those with chronic conditions, or anyone on multiple medications—especially those for blood pressure, mental health, or diabetes—are the most vulnerable. But if you enjoy festivals, outdoor work, or travel, heat and pills could pose overlooked hazards. A prescription for summer safety What if everyone had a 'heat plan' alongside their morning meds? The CDC suggests that clinicians discuss temporary dose adjustments, hydration plans, and clear hot-weather check-ins with high-risk patients. Likewise, the UKHSA encourages pharmacists and health professionals to proactively reach out ahead of heatwaves with leaflets, alerts, and storage guidance. Even simple moves—keeping extra water by your bed, storing meds in a cool place, or turning on the fan during midday—can make a big difference when the mercury rises. Heat is a drug amplifier If you're breezing out in the sun this summer, your medication isn't just a pill in a cabinet—it's part of how your body reacts to heat. The UKHSA really isn't joking when they stress the double-whammy of high temps and everyday meds. Because in sweltering summer, keeping cool is about more than comfort—it's about staying safe while on the meds that help you live your best life.
Time of India
07-07-2025
- Time of India
New investigation reveals potentially fatal side effects of popular weight-loss drugs
Image credits: Getty Images Every coin has two sides and so does every miracle. While it gives a person an advantage, it also gives them a disadvantage. Popular weight-loss drugs like Ozempic have been revolutionary in weight loss with a plethora of celebrities jumping on the bandwagon. However, their side-effects including tooth decay, droopy face, saggy butt and hair loss have not been hidden from the eyes of all. Now, a UK regulator is shedding light on much more serious and potentially fatal side effects of these drugs. The UK's Medicines and Healthcare products Regulatory Agency's (MHRA) Yellow Card scheme, the official system for collecting and monitoring reports of suspected side effects or reactions to drugs and devices, has recently received over 400 reports of serious pancreas trouble from users of GLP-1. Image credits: Getty Images Acute pancreatitis is a sudden and extremely painful inflammation of the pancreas that causes people severe abdominal pain, nausea and fever. In the UK, there have been at least 10 deaths linked to this condition among users of GLP-1. Among the users of Mounjaro, there have been 181 reported cases of acute or chronic pancreatitis with 5 deaths. While the pamphlets on these famous drugs note that pancreatitis is an uncommon reaction that only affects one in 100 users, the condition is deemed serious enough to require an investigation. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like CEO da Apple Impressionado: O Melhor App Para Intelectuais do Mundo Todo Blinkist Undo Image credits: Getty Images 'Sometimes genes can influence the side‑effects an individual experiences when taking a medicine,' the MHRA told The Guardian. Thus along with Genomics England, MHRA is launching a new study to see if people's genes put them at a higher risk of developing pancreatitis while taking GLP-1 drugs. Those who have pancreatitis while using the jabs will be asked to provide a saliva sample and have their genes tested. Novo Nordisk, which produces Ozempic and Wegovy, advised people to take the medications only for their approved indications and under the strict supervision of a healthcare professional. 'We continuously collect safety data on our marketed GLP-1 medicines and work closely with the authorities to ensure patient safety. The benefit-risk profile of our GLP-1 medicines remains positive, and we welcome any new research that will improve our understanding of treatments for people living with chronic diseases," they told the outlet.
Business Standard
07-07-2025
- Business Standard
Biocon Biologics receives UK MHRA marketing authorisations for Vevzuo and Evfraxy
Biocon Biologics announced that the Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorisations in the United Kingdom (UK) for Vevzuo and Evfraxy, biosimilars of Denosumab. Vevzuo is authorized for the prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone. Vevzuo is also authorized for the treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity. Evfraxy is authorized for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women this significantly reduces the risk of vertebral, non-vertebral, and hip fractures. Furthermore, Evfraxy is authorized for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. In men with prostate cancer receiving hormone ablation, this significantly reduces the risk of vertebral fractures. Evfraxy is also authorized for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture. Clinical data showed that both Denosumab biosimilars have comparable safety and efficacy to the reference product. In Europe, the European Commission (EC) recently granted marketing authorisation for Biocon Biologics Denosumab biosimilars, allowing their commercialization in all European Union (EU) member states and the European Economic Area (EEA).
